União Química
Date: Feb 2015
Client: União Química
Counterparty: Novartis
Industry: Healthcare
Amount: Undisclosed amount
Transaction:
Landmark Alantra acted as exclusive financial advisor of União Química Farmacêutica Nacional, one of Brazil's leading pharmaceutical company, in the structuring and negotiation of a long term manufacture agreement of Novartis medicines, one of world´s largest pharmaceutical company, at Taboão da Serra/SP facility. This plant manufactures medicines to supply the Latin American market.
Besides the manufacturing agreement, the transaction also included the acquisition of Taboão da Serra/SP facility by União Química.
Feb 2015
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/uniao%20quimica.jpg?width=130&height=48&name=uniao%20quimica.jpg)
on a long-term production agreement with
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/novartis.png?width=130&height=48&name=novartis.png)
Undisclosed amount
Similar transactions
Nov 2021
![](https://landmark-cap.com/hs-fs/hubfs/Banderas%20Pa%C3%ADses/bandera_francia.jpg?width=27&height=18&name=bandera_francia.jpg)
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/centrovet.png?width=130&height=48&name=centrovet.png)
on the sale of 34% of the shares to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/virbac.jpg?width=130&height=48&name=virbac.jpg)
With this transaction, Virbac completes the acquisition of 100% of the company since the initial purchase in 2012
Leer más